| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 57 | 2023 | 2796 | 6.720 |
Why?
|
| Brain Neoplasms | 51 | 2024 | 4849 | 3.780 |
Why?
|
| Papillomavirus Infections | 18 | 2023 | 980 | 3.200 |
Why?
|
| Uterine Cervical Dysplasia | 9 | 2023 | 219 | 2.930 |
Why?
|
| Glioma | 28 | 2021 | 1963 | 2.870 |
Why?
|
| Uterine Cervical Neoplasms | 17 | 2023 | 1833 | 2.840 |
Why?
|
| Sarcoma, Kaposi | 12 | 2023 | 187 | 2.770 |
Why?
|
| Central Nervous System Neoplasms | 10 | 2023 | 502 | 2.630 |
Why?
|
| Child | 153 | 2024 | 29154 | 2.530 |
Why?
|
| Medulloblastoma | 14 | 2023 | 540 | 2.480 |
Why?
|
| HIV Infections | 19 | 2023 | 2134 | 2.290 |
Why?
|
| Cerebellar Neoplasms | 12 | 2023 | 434 | 2.240 |
Why?
|
| Polymorphism, Single Nucleotide | 33 | 2020 | 4549 | 2.190 |
Why?
|
| Genetic Predisposition to Disease | 34 | 2023 | 5539 | 1.730 |
Why?
|
| Child, Preschool | 88 | 2023 | 16273 | 1.720 |
Why?
|
| DNA, Viral | 12 | 2023 | 694 | 1.710 |
Why?
|
| Case-Control Studies | 47 | 2023 | 6100 | 1.510 |
Why?
|
| Papillomaviridae | 11 | 2023 | 624 | 1.490 |
Why?
|
| Adolescent | 96 | 2023 | 31252 | 1.470 |
Why?
|
| Humans | 261 | 2024 | 261506 | 1.460 |
Why?
|
| Female | 176 | 2024 | 141928 | 1.390 |
Why?
|
| Risk Factors | 64 | 2023 | 17523 | 1.380 |
Why?
|
| Methotrexate | 8 | 2023 | 999 | 1.340 |
Why?
|
| SEER Program | 13 | 2022 | 1000 | 1.320 |
Why?
|
| Air Pollutants | 7 | 2019 | 139 | 1.310 |
Why?
|
| Infant | 63 | 2023 | 13310 | 1.290 |
Why?
|
| Roseolovirus Infections | 3 | 2013 | 39 | 1.290 |
Why?
|
| Residence Characteristics | 7 | 2021 | 348 | 1.240 |
Why?
|
| Genotype | 27 | 2023 | 4109 | 1.240 |
Why?
|
| Herpesvirus 6, Human | 3 | 2013 | 81 | 1.240 |
Why?
|
| Hypersensitivity | 5 | 2022 | 216 | 1.220 |
Why?
|
| Male | 148 | 2024 | 123000 | 1.210 |
Why?
|
| Human papillomavirus 16 | 7 | 2023 | 256 | 1.170 |
Why?
|
| Leukemia | 12 | 2023 | 1635 | 1.130 |
Why?
|
| Rhabdomyosarcoma | 7 | 2024 | 341 | 1.080 |
Why?
|
| Metabolomics | 4 | 2021 | 478 | 1.050 |
Why?
|
| Texas | 31 | 2023 | 6311 | 1.040 |
Why?
|
| Health Status Disparities | 5 | 2021 | 291 | 1.020 |
Why?
|
| Genome-Wide Association Study | 16 | 2023 | 2265 | 1.020 |
Why?
|
| Neoplasms | 16 | 2023 | 15193 | 1.010 |
Why?
|
| Craniospinal Irradiation | 2 | 2023 | 128 | 1.010 |
Why?
|
| Adult | 90 | 2023 | 77950 | 1.000 |
Why?
|
| Papillomavirus Vaccines | 3 | 2017 | 195 | 1.000 |
Why?
|
| Genetic Variation | 6 | 2019 | 2086 | 0.980 |
Why?
|
| Epoxide Hydrolases | 3 | 2013 | 53 | 0.980 |
Why?
|
| DNA Methylation | 7 | 2020 | 2669 | 0.960 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2021 | 268 | 0.950 |
Why?
|
| Ependymoma | 4 | 2023 | 242 | 0.930 |
Why?
|
| Vehicle Emissions | 4 | 2019 | 29 | 0.920 |
Why?
|
| Young Adult | 48 | 2023 | 21445 | 0.910 |
Why?
|
| Endogenous Retroviruses | 1 | 2023 | 41 | 0.910 |
Why?
|
| Malnutrition | 2 | 2023 | 218 | 0.880 |
Why?
|
| Histamine Antagonists | 2 | 2013 | 17 | 0.870 |
Why?
|
| Neuroectodermal Tumors, Primitive | 5 | 2023 | 100 | 0.870 |
Why?
|
| Warts | 2 | 2012 | 19 | 0.860 |
Why?
|
| Gene-Environment Interaction | 3 | 2015 | 166 | 0.850 |
Why?
|
| Folic Acid | 3 | 2013 | 349 | 0.850 |
Why?
|
| Asparaginase | 1 | 2022 | 184 | 0.820 |
Why?
|
| Hazardous Substances | 1 | 2021 | 27 | 0.820 |
Why?
|
| Registries | 14 | 2023 | 2170 | 0.810 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 12 | 0.790 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2021 | 83 | 0.770 |
Why?
|
| Osteomyelitis | 1 | 2023 | 236 | 0.770 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2012 | 142 | 0.770 |
Why?
|
| Leukemia, Myeloid, Acute | 12 | 2023 | 6915 | 0.760 |
Why?
|
| Prevalence | 12 | 2022 | 3260 | 0.760 |
Why?
|
| Human papillomavirus 18 | 3 | 2023 | 43 | 0.760 |
Why?
|
| Bacteremia | 2 | 2023 | 689 | 0.750 |
Why?
|
| Papanicolaou Test | 4 | 2021 | 141 | 0.740 |
Why?
|
| Incidence | 23 | 2023 | 5673 | 0.730 |
Why?
|
| Anemia | 2 | 2023 | 689 | 0.720 |
Why?
|
| Venous Thromboembolism | 2 | 2022 | 335 | 0.720 |
Why?
|
| Benzene | 4 | 2023 | 45 | 0.720 |
Why?
|
| Pancreatitis | 1 | 2022 | 267 | 0.720 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 207 | 0.720 |
Why?
|
| Cancer Survivors | 5 | 2020 | 650 | 0.710 |
Why?
|
| Premature Birth | 3 | 2021 | 407 | 0.700 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2018 | 521 | 0.690 |
Why?
|
| Elastin | 1 | 2019 | 49 | 0.690 |
Why?
|
| Emigrants and Immigrants | 3 | 2021 | 147 | 0.690 |
Why?
|
| Age Factors | 15 | 2021 | 5377 | 0.670 |
Why?
|
| Logistic Models | 17 | 2023 | 3441 | 0.670 |
Why?
|
| Infant, Newborn | 30 | 2022 | 8223 | 0.660 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 333 | 0.650 |
Why?
|
| Virus Integration | 3 | 2017 | 76 | 0.650 |
Why?
|
| Cigarette Smoking | 1 | 2019 | 88 | 0.630 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 368 | 0.630 |
Why?
|
| Nerve Sheath Neoplasms | 2 | 2018 | 79 | 0.610 |
Why?
|
| F2-Isoprostanes | 3 | 2023 | 28 | 0.610 |
Why?
|
| Autoimmunity | 1 | 2019 | 263 | 0.600 |
Why?
|
| Cytomegalovirus Infections | 3 | 2013 | 462 | 0.600 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 122 | 0.600 |
Why?
|
| United States | 24 | 2023 | 15433 | 0.590 |
Why?
|
| Middle Aged | 53 | 2019 | 86204 | 0.590 |
Why?
|
| Models, Genetic | 5 | 2014 | 1113 | 0.580 |
Why?
|
| Family Health | 3 | 2013 | 325 | 0.570 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 482 | 0.570 |
Why?
|
| Haplotypes | 5 | 2013 | 856 | 0.570 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2019 | 336 | 0.560 |
Why?
|
| Life Style | 1 | 2019 | 612 | 0.550 |
Why?
|
| Retrospective Studies | 35 | 2023 | 37905 | 0.540 |
Why?
|
| Ear Diseases | 1 | 2015 | 21 | 0.540 |
Why?
|
| Neuroblastoma | 4 | 2023 | 686 | 0.540 |
Why?
|
| Autoantibodies | 1 | 2019 | 576 | 0.520 |
Why?
|
| Health Promotion | 1 | 2019 | 502 | 0.520 |
Why?
|
| Superoxide Dismutase | 2 | 2015 | 266 | 0.520 |
Why?
|
| Specimen Handling | 3 | 2020 | 299 | 0.520 |
Why?
|
| Oxidative Stress | 6 | 2021 | 1129 | 0.520 |
Why?
|
| Self Care | 2 | 2023 | 224 | 0.510 |
Why?
|
| Fatigue | 9 | 2023 | 1239 | 0.510 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2016 | 317 | 0.510 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 799 | 0.510 |
Why?
|
| Genetic Association Studies | 5 | 2017 | 1084 | 0.500 |
Why?
|
| Viral Load | 2 | 2018 | 493 | 0.500 |
Why?
|
| Particulate Matter | 2 | 2015 | 86 | 0.500 |
Why?
|
| Pediatric Obesity | 1 | 2019 | 364 | 0.490 |
Why?
|
| Hypospadias | 3 | 2020 | 77 | 0.490 |
Why?
|
| Reduced Folate Carrier Protein | 1 | 2013 | 20 | 0.480 |
Why?
|
| Newspapers as Topic | 1 | 2013 | 7 | 0.480 |
Why?
|
| Prognosis | 27 | 2022 | 21713 | 0.480 |
Why?
|
| Odds Ratio | 13 | 2019 | 2316 | 0.480 |
Why?
|
| Atlases as Topic | 1 | 2014 | 42 | 0.480 |
Why?
|
| Journalism, Medical | 1 | 2013 | 11 | 0.480 |
Why?
|
| Smoking | 3 | 2016 | 2440 | 0.470 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2013 | 24 | 0.470 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 1033 | 0.470 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 500 | 0.470 |
Why?
|
| Meningococcal Vaccines | 1 | 2013 | 31 | 0.470 |
Why?
|
| Herpesvirus 8, Human | 4 | 2023 | 102 | 0.470 |
Why?
|
| Condylomata Acuminata | 1 | 2013 | 26 | 0.470 |
Why?
|
| Cytomegalovirus | 4 | 2015 | 482 | 0.470 |
Why?
|
| Environmental Exposure | 4 | 2021 | 288 | 0.470 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2014 | 70 | 0.460 |
Why?
|
| Birth Weight | 6 | 2023 | 374 | 0.450 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2013 | 70 | 0.450 |
Why?
|
| Mexican Americans | 1 | 2015 | 322 | 0.450 |
Why?
|
| Cognition Disorders | 2 | 2016 | 786 | 0.450 |
Why?
|
| Cisplatin | 2 | 2017 | 2432 | 0.440 |
Why?
|
| Neurilemmoma | 1 | 2014 | 127 | 0.440 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2013 | 78 | 0.440 |
Why?
|
| Immunoglobulin E | 1 | 2013 | 163 | 0.440 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 2 | 2023 | 64 | 0.440 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 265 | 0.440 |
Why?
|
| Risk-Taking | 1 | 2013 | 133 | 0.440 |
Why?
|
| Cohort Studies | 13 | 2024 | 9244 | 0.430 |
Why?
|
| Aged | 31 | 2023 | 70117 | 0.430 |
Why?
|
| Sex Factors | 6 | 2021 | 2139 | 0.430 |
Why?
|
| Encephalitis, Viral | 1 | 2012 | 30 | 0.430 |
Why?
|
| Glutathione Transferase | 2 | 2013 | 359 | 0.430 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2012 | 13 | 0.430 |
Why?
|
| Air Pollutants, Occupational | 1 | 2012 | 30 | 0.420 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2019 | 595 | 0.420 |
Why?
|
| Overweight | 3 | 2022 | 484 | 0.420 |
Why?
|
| Herpesviridae Infections | 2 | 2018 | 175 | 0.410 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 482 | 0.410 |
Why?
|
| Anus Neoplasms | 2 | 2013 | 411 | 0.400 |
Why?
|
| Biomarkers | 9 | 2023 | 5047 | 0.400 |
Why?
|
| Supratentorial Neoplasms | 1 | 2011 | 78 | 0.390 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 3203 | 0.390 |
Why?
|
| Cross-Sectional Studies | 10 | 2023 | 4314 | 0.390 |
Why?
|
| Hyperbilirubinemia | 2 | 2022 | 78 | 0.390 |
Why?
|
| Bayes Theorem | 3 | 2023 | 1021 | 0.390 |
Why?
|
| Genetic Linkage | 1 | 2012 | 512 | 0.390 |
Why?
|
| Maternal Exposure | 4 | 2020 | 160 | 0.390 |
Why?
|
| Chromosomes, Human | 1 | 2012 | 295 | 0.390 |
Why?
|
| Anal Canal | 1 | 2012 | 238 | 0.380 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 860 | 0.380 |
Why?
|
| Arachidonic Acid | 1 | 2011 | 118 | 0.380 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 1021 | 0.380 |
Why?
|
| Obesity | 5 | 2020 | 2884 | 0.380 |
Why?
|
| Internet | 2 | 2022 | 706 | 0.370 |
Why?
|
| Proportional Hazards Models | 10 | 2023 | 4988 | 0.370 |
Why?
|
| Antibodies, Viral | 2 | 2016 | 1320 | 0.370 |
Why?
|
| Germ-Line Mutation | 4 | 2021 | 1046 | 0.370 |
Why?
|
| Biomarkers, Tumor | 9 | 2021 | 10331 | 0.360 |
Why?
|
| Hepatoblastoma | 2 | 2023 | 215 | 0.360 |
Why?
|
| Early Detection of Cancer | 6 | 2023 | 1258 | 0.350 |
Why?
|
| Malawi | 6 | 2023 | 378 | 0.350 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2012 | 362 | 0.340 |
Why?
|
| Risk Assessment | 8 | 2018 | 6869 | 0.340 |
Why?
|
| Sleep Wake Disorders | 4 | 2021 | 348 | 0.340 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2008 | 22 | 0.340 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2023 | 113 | 0.340 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 1021 | 0.340 |
Why?
|
| Survivors | 8 | 2023 | 1031 | 0.340 |
Why?
|
| Oncology Nursing | 3 | 2020 | 51 | 0.330 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2023 | 1299 | 0.330 |
Why?
|
| Histamine H1 Antagonists | 1 | 2008 | 25 | 0.330 |
Why?
|
| Genome, Human | 2 | 2020 | 1869 | 0.320 |
Why?
|
| Glioblastoma | 5 | 2015 | 1797 | 0.320 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2022 | 1039 | 0.320 |
Why?
|
| Interleukin-13 | 1 | 2008 | 135 | 0.320 |
Why?
|
| Medical Oncology | 4 | 2023 | 1423 | 0.320 |
Why?
|
| Syndrome | 6 | 2022 | 1351 | 0.320 |
Why?
|
| Cesarean Section | 3 | 2023 | 367 | 0.320 |
Why?
|
| Socioeconomic Factors | 4 | 2020 | 1225 | 0.310 |
Why?
|
| Interleukin-4 | 1 | 2008 | 284 | 0.310 |
Why?
|
| Sarcoma | 2 | 2019 | 1725 | 0.310 |
Why?
|
| Metabolome | 2 | 2021 | 344 | 0.310 |
Why?
|
| Sex Workers | 2 | 2018 | 5 | 0.310 |
Why?
|
| Vaginal Douching | 2 | 2018 | 5 | 0.310 |
Why?
|
| Follow-Up Studies | 14 | 2021 | 14889 | 0.300 |
Why?
|
| Ploidies | 1 | 2007 | 248 | 0.300 |
Why?
|
| Gammaherpesvirinae | 1 | 2007 | 12 | 0.300 |
Why?
|
| Asthma | 3 | 2013 | 871 | 0.300 |
Why?
|
| Exome | 3 | 2017 | 1239 | 0.290 |
Why?
|
| Cranial Irradiation | 3 | 2020 | 315 | 0.290 |
Why?
|
| Creatinine | 3 | 2023 | 531 | 0.280 |
Why?
|
| Pregnancy | 11 | 2023 | 7573 | 0.280 |
Why?
|
| Sweden | 4 | 2019 | 70 | 0.280 |
Why?
|
| Neoplasm Grading | 4 | 2021 | 1742 | 0.280 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2021 | 534 | 0.280 |
Why?
|
| Lamivudine | 2 | 2022 | 28 | 0.280 |
Why?
|
| Unsafe Sex | 2 | 2017 | 21 | 0.270 |
Why?
|
| Chromosome Aberrations | 2 | 2017 | 1960 | 0.270 |
Why?
|
| International Cooperation | 2 | 2018 | 323 | 0.270 |
Why?
|
| Pediatrics | 4 | 2021 | 1141 | 0.270 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 14289 | 0.270 |
Why?
|
| Pilot Projects | 5 | 2019 | 2803 | 0.270 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2022 | 598 | 0.260 |
Why?
|
| Osteosarcoma | 2 | 2023 | 929 | 0.260 |
Why?
|
| Cognition | 3 | 2021 | 968 | 0.260 |
Why?
|
| Gestational Age | 4 | 2023 | 1069 | 0.250 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2005 | 133 | 0.250 |
Why?
|
| RNA, Viral | 2 | 2023 | 671 | 0.250 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2018 | 261 | 0.250 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2007 | 665 | 0.250 |
Why?
|
| Minority Groups | 3 | 2023 | 322 | 0.240 |
Why?
|
| Pedigree | 3 | 2013 | 1890 | 0.240 |
Why?
|
| Poverty Areas | 2 | 2021 | 37 | 0.240 |
Why?
|
| Prospective Studies | 9 | 2024 | 12873 | 0.240 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2015 | 235 | 0.230 |
Why?
|
| Hearing Loss | 2 | 2017 | 153 | 0.230 |
Why?
|
| Insecticides | 1 | 2023 | 49 | 0.230 |
Why?
|
| Nucleic Acids | 1 | 2023 | 43 | 0.230 |
Why?
|
| Anticoagulants | 2 | 2021 | 787 | 0.230 |
Why?
|
| Severe Acute Malnutrition | 1 | 2023 | 23 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2016 | 6207 | 0.230 |
Why?
|
| Ovarian Reserve | 1 | 2023 | 10 | 0.230 |
Why?
|
| Parents | 3 | 2019 | 998 | 0.230 |
Why?
|
| Genetic Markers | 3 | 2015 | 974 | 0.230 |
Why?
|
| Neoplasms, Second Primary | 2 | 2024 | 1350 | 0.230 |
Why?
|
| Social Class | 2 | 2020 | 310 | 0.220 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2023 | 16 | 0.220 |
Why?
|
| Leuprolide | 1 | 2023 | 65 | 0.220 |
Why?
|
| Intelligence | 1 | 2023 | 126 | 0.220 |
Why?
|
| DNA End-Joining Repair | 1 | 2023 | 86 | 0.220 |
Why?
|
| Mass Screening | 5 | 2023 | 1509 | 0.220 |
Why?
|
| Astrocytoma | 2 | 2023 | 321 | 0.220 |
Why?
|
| Databases, Genetic | 2 | 2023 | 745 | 0.220 |
Why?
|
| Neuropsychological Tests | 5 | 2021 | 1178 | 0.220 |
Why?
|
| Immunoglobulins | 1 | 2023 | 266 | 0.210 |
Why?
|
| Mutism | 1 | 2022 | 21 | 0.210 |
Why?
|
| Vaginal Smears | 4 | 2023 | 192 | 0.210 |
Why?
|
| Lod Score | 2 | 2012 | 157 | 0.210 |
Why?
|
| Antioxidants | 2 | 2018 | 507 | 0.210 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2023 | 77 | 0.210 |
Why?
|
| Thrombocytopenia | 2 | 2022 | 846 | 0.210 |
Why?
|
| Feasibility Studies | 2 | 2019 | 2292 | 0.210 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 3230 | 0.210 |
Why?
|
| Chromatin | 1 | 2007 | 942 | 0.210 |
Why?
|
| Enterobacter | 1 | 2021 | 20 | 0.210 |
Why?
|
| Hodgkin Disease | 2 | 2023 | 1429 | 0.210 |
Why?
|
| Vulnerable Populations | 1 | 2023 | 167 | 0.210 |
Why?
|
| Pain | 5 | 2022 | 1658 | 0.210 |
Why?
|
| RNA, Messenger | 3 | 2007 | 6150 | 0.210 |
Why?
|
| Risk | 6 | 2019 | 1972 | 0.200 |
Why?
|
| Maternal Age | 2 | 2022 | 152 | 0.200 |
Why?
|
| Tooth, Deciduous | 1 | 2021 | 6 | 0.200 |
Why?
|
| Rothmund-Thomson Syndrome | 1 | 2022 | 54 | 0.200 |
Why?
|
| Immediate-Early Proteins | 2 | 2015 | 107 | 0.200 |
Why?
|
| Mucositis | 1 | 2022 | 148 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 3 | 2023 | 2992 | 0.200 |
Why?
|
| Thrombocytosis | 1 | 2022 | 121 | 0.200 |
Why?
|
| Mothers | 2 | 2023 | 410 | 0.200 |
Why?
|
| Spectrometry, Fluorescence | 3 | 2012 | 209 | 0.200 |
Why?
|
| RecQ Helicases | 1 | 2022 | 102 | 0.200 |
Why?
|
| Maltose | 1 | 2021 | 22 | 0.200 |
Why?
|
| Cerebellar Diseases | 1 | 2022 | 89 | 0.200 |
Why?
|
| MAP Kinase Kinase Kinase 2 | 1 | 2021 | 14 | 0.200 |
Why?
|
| Rhinitis | 1 | 2021 | 37 | 0.200 |
Why?
|
| Neurocognitive Disorders | 1 | 2021 | 69 | 0.200 |
Why?
|
| Longitudinal Studies | 7 | 2021 | 1945 | 0.200 |
Why?
|
| Hypophosphatemia | 1 | 2021 | 26 | 0.200 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2021 | 69 | 0.200 |
Why?
|
| Adrenal Insufficiency | 1 | 2021 | 49 | 0.200 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2022 | 70 | 0.190 |
Why?
|
| Phosphorus | 1 | 2021 | 65 | 0.190 |
Why?
|
| Body Mass Index | 4 | 2020 | 2203 | 0.190 |
Why?
|
| Demography | 1 | 2022 | 435 | 0.190 |
Why?
|
| Causality | 1 | 2021 | 178 | 0.190 |
Why?
|
| Acute Disease | 2 | 2023 | 2422 | 0.190 |
Why?
|
| Language Development Disorders | 1 | 2022 | 167 | 0.190 |
Why?
|
| DNA-Binding Proteins | 4 | 2019 | 4821 | 0.190 |
Why?
|
| Congresses as Topic | 3 | 2018 | 298 | 0.190 |
Why?
|
| Paternal Exposure | 1 | 2020 | 9 | 0.190 |
Why?
|
| Ferric Compounds | 1 | 2021 | 73 | 0.190 |
Why?
|
| Drug Hypersensitivity | 1 | 2022 | 128 | 0.190 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2020 | 20 | 0.190 |
Why?
|
| DNA Repair | 4 | 2021 | 1872 | 0.190 |
Why?
|
| Neonatal Screening | 2 | 2020 | 165 | 0.190 |
Why?
|
| Interferon Type I | 2 | 2013 | 250 | 0.190 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2022 | 193 | 0.190 |
Why?
|
| Radiation, Ionizing | 1 | 2021 | 187 | 0.180 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 21 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 362 | 0.180 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2021 | 158 | 0.180 |
Why?
|
| Monocytes | 2 | 2023 | 788 | 0.180 |
Why?
|
| Weight Gain | 2 | 2023 | 464 | 0.180 |
Why?
|
| Medically Underserved Area | 2 | 2023 | 101 | 0.180 |
Why?
|
| Bone Neoplasms | 2 | 2023 | 2576 | 0.180 |
Why?
|
| Hypothyroidism | 1 | 2021 | 204 | 0.180 |
Why?
|
| Quality of Life | 4 | 2023 | 4532 | 0.180 |
Why?
|
| Patient Selection | 1 | 2007 | 2055 | 0.180 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2019 | 18 | 0.180 |
Why?
|
| Canada | 2 | 2017 | 429 | 0.180 |
Why?
|
| Europe | 2 | 2021 | 649 | 0.180 |
Why?
|
| Radiation Exposure | 1 | 2020 | 73 | 0.170 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 252 | 0.170 |
Why?
|
| Diacylglycerol Kinase | 1 | 2019 | 23 | 0.170 |
Why?
|
| Sarcoma, Ewing | 1 | 2023 | 406 | 0.170 |
Why?
|
| Child Development | 1 | 2021 | 255 | 0.170 |
Why?
|
| Child Behavior Disorders | 1 | 2019 | 68 | 0.170 |
Why?
|
| Congenital Abnormalities | 2 | 2019 | 260 | 0.170 |
Why?
|
| Point-of-Care Systems | 2 | 2023 | 196 | 0.170 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 5159 | 0.170 |
Why?
|
| Butadienes | 2 | 2015 | 35 | 0.170 |
Why?
|
| Colposcopy | 3 | 2021 | 78 | 0.170 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 1763 | 0.170 |
Why?
|
| Reproductive Tract Infections | 1 | 2018 | 1 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 538 | 0.170 |
Why?
|
| Leukocyte Elastase | 1 | 2019 | 70 | 0.170 |
Why?
|
| Vital Capacity | 1 | 2019 | 131 | 0.170 |
Why?
|
| Infant Formula | 2 | 2017 | 91 | 0.170 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2021 | 128 | 0.170 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 615 | 0.160 |
Why?
|
| Retinal Neoplasms | 1 | 2020 | 144 | 0.160 |
Why?
|
| Retinoblastoma | 1 | 2020 | 200 | 0.160 |
Why?
|
| Antifungal Agents | 2 | 2021 | 834 | 0.160 |
Why?
|
| Nitrosative Stress | 1 | 2018 | 3 | 0.160 |
Why?
|
| Paternal Age | 1 | 2018 | 11 | 0.160 |
Why?
|
| Social Determinants of Health | 1 | 2019 | 97 | 0.160 |
Why?
|
| Survival Rate | 6 | 2020 | 12221 | 0.160 |
Why?
|
| Chromosome Mapping | 2 | 2012 | 1471 | 0.160 |
Why?
|
| Optic Nerve Glioma | 1 | 2018 | 31 | 0.160 |
Why?
|
| Exercise | 3 | 2023 | 1183 | 0.160 |
Why?
|
| Air Pollution | 2 | 2019 | 87 | 0.160 |
Why?
|
| Smokers | 1 | 2019 | 143 | 0.160 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 598 | 0.160 |
Why?
|
| Smad6 Protein | 1 | 2017 | 14 | 0.160 |
Why?
|
| Research | 2 | 2022 | 415 | 0.160 |
Why?
|
| Forced Expiratory Volume | 1 | 2019 | 314 | 0.150 |
Why?
|
| Interleukin-1beta | 1 | 2019 | 300 | 0.150 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2019 | 360 | 0.150 |
Why?
|
| Prostatic Neoplasms | 2 | 2014 | 5767 | 0.150 |
Why?
|
| Mycoses | 1 | 2021 | 386 | 0.150 |
Why?
|
| Hydroxyurea | 1 | 2018 | 204 | 0.150 |
Why?
|
| Vaccination Coverage | 1 | 2017 | 37 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2021 | 329 | 0.150 |
Why?
|
| Body Weights and Measures | 1 | 2017 | 52 | 0.150 |
Why?
|
| Repressor Proteins | 1 | 2005 | 1664 | 0.150 |
Why?
|
| Interleukin-6 | 2 | 2019 | 1038 | 0.150 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2022 | 297 | 0.150 |
Why?
|
| Survival Analysis | 3 | 2021 | 9180 | 0.150 |
Why?
|
| Neoplasm, Residual | 2 | 2022 | 1656 | 0.150 |
Why?
|
| Electronic Health Records | 2 | 2022 | 929 | 0.150 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 321 | 0.150 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2016 | 23 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 15862 | 0.150 |
Why?
|
| Enoxaparin | 1 | 2017 | 66 | 0.150 |
Why?
|
| Gene Frequency | 3 | 2019 | 1163 | 0.150 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 783 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 245 | 0.150 |
Why?
|
| Down Syndrome | 1 | 2019 | 226 | 0.150 |
Why?
|
| Asia | 1 | 2017 | 142 | 0.150 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2017 | 83 | 0.140 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2016 | 69 | 0.140 |
Why?
|
| Tyrosine | 1 | 2018 | 498 | 0.140 |
Why?
|
| Factor Xa Inhibitors | 1 | 2017 | 70 | 0.140 |
Why?
|
| Germ Cells | 3 | 2024 | 335 | 0.140 |
Why?
|
| Lymphoma, B-Cell | 1 | 2023 | 895 | 0.140 |
Why?
|
| Sex Work | 1 | 2016 | 5 | 0.140 |
Why?
|
| Chickenpox | 1 | 2016 | 31 | 0.140 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2016 | 27 | 0.140 |
Why?
|
| Lymphoma | 2 | 2015 | 1467 | 0.140 |
Why?
|
| Nausea | 4 | 2020 | 525 | 0.140 |
Why?
|
| Oropharynx | 1 | 2016 | 74 | 0.140 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2016 | 65 | 0.140 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 677 | 0.140 |
Why?
|
| Denmark | 2 | 2013 | 48 | 0.140 |
Why?
|
| Air Pollutants, Radioactive | 1 | 2015 | 6 | 0.140 |
Why?
|
| Thrombopoietin | 1 | 2016 | 77 | 0.140 |
Why?
|
| Radon | 1 | 2015 | 11 | 0.140 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2016 | 239 | 0.140 |
Why?
|
| Calreticulin | 1 | 2016 | 74 | 0.140 |
Why?
|
| Vincristine | 2 | 2017 | 1511 | 0.140 |
Why?
|
| Interviews as Topic | 3 | 2018 | 497 | 0.140 |
Why?
|
| Sepsis | 1 | 2021 | 652 | 0.140 |
Why?
|
| Intellectual Disability | 1 | 2023 | 1032 | 0.130 |
Why?
|
| Carcinoma | 1 | 2007 | 2578 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 739 | 0.130 |
Why?
|
| Population Dynamics | 1 | 2015 | 42 | 0.130 |
Why?
|
| Immunoassay | 1 | 2016 | 216 | 0.130 |
Why?
|
| HIV | 1 | 2017 | 229 | 0.130 |
Why?
|
| Self-Examination | 1 | 2015 | 12 | 0.130 |
Why?
|
| Recurrence | 2 | 2021 | 4758 | 0.130 |
Why?
|
| Liver Neoplasms | 2 | 2023 | 4557 | 0.130 |
Why?
|
| Air Pollution, Indoor | 1 | 2015 | 39 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2023 | 573 | 0.130 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 2927 | 0.130 |
Why?
|
| Glutathione S-Transferase pi | 2 | 2012 | 69 | 0.130 |
Why?
|
| Alleles | 3 | 2017 | 2437 | 0.130 |
Why?
|
| Aspirin | 1 | 2018 | 455 | 0.130 |
Why?
|
| Biomedical Research | 2 | 2012 | 806 | 0.130 |
Why?
|
| Molecular Epidemiology | 1 | 2015 | 246 | 0.130 |
Why?
|
| Developmental Disabilities | 1 | 2019 | 674 | 0.130 |
Why?
|
| Interferon-gamma | 1 | 2019 | 1144 | 0.130 |
Why?
|
| Iron-Regulatory Proteins | 1 | 2014 | 11 | 0.130 |
Why?
|
| Depression | 2 | 2022 | 1715 | 0.130 |
Why?
|
| San Francisco | 2 | 2013 | 19 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 339 | 0.120 |
Why?
|
| Viral Matrix Proteins | 1 | 2015 | 201 | 0.120 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2017 | 328 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 787 | 0.120 |
Why?
|
| Thrombosis | 1 | 2021 | 781 | 0.120 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2014 | 24 | 0.120 |
Why?
|
| Cities | 1 | 2014 | 49 | 0.120 |
Why?
|
| Aged, 80 and over | 8 | 2018 | 29902 | 0.120 |
Why?
|
| Thrombocythemia, Essential | 1 | 2016 | 162 | 0.120 |
Why?
|
| Phosphoproteins | 2 | 2021 | 1152 | 0.120 |
Why?
|
| Antigens, Viral | 2 | 2016 | 471 | 0.120 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2013 | 4 | 0.120 |
Why?
|
| Membrane Proteins | 2 | 2015 | 2819 | 0.120 |
Why?
|
| Search Engine | 1 | 2013 | 21 | 0.120 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2014 | 110 | 0.120 |
Why?
|
| Mass Media | 1 | 2013 | 36 | 0.120 |
Why?
|
| Affective Symptoms | 1 | 2014 | 102 | 0.120 |
Why?
|
| Bone Marrow | 1 | 2021 | 2358 | 0.120 |
Why?
|
| Eating | 1 | 2016 | 421 | 0.120 |
Why?
|
| Emigration and Immigration | 1 | 2014 | 86 | 0.120 |
Why?
|
| Proteomics | 1 | 2021 | 1380 | 0.120 |
Why?
|
| Infant Food | 1 | 2013 | 89 | 0.110 |
Why?
|
| Spectrum Analysis | 2 | 2011 | 139 | 0.110 |
Why?
|
| Urticaria | 1 | 2013 | 23 | 0.110 |
Why?
|
| Eczema | 1 | 2013 | 37 | 0.110 |
Why?
|
| Polymorphism, Genetic | 3 | 2021 | 1450 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 1756 | 0.110 |
Why?
|
| Peptide Fragments | 1 | 2019 | 1271 | 0.110 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2013 | 42 | 0.110 |
Why?
|
| Israel | 1 | 2013 | 53 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 2359 | 0.110 |
Why?
|
| Bibliometrics | 1 | 2013 | 71 | 0.110 |
Why?
|
| Vaccination | 2 | 2016 | 1123 | 0.110 |
Why?
|
| Allergy and Immunology | 1 | 2013 | 29 | 0.110 |
Why?
|
| DNA Ligases | 2 | 2010 | 63 | 0.110 |
Why?
|
| Xenobiotics | 1 | 2013 | 44 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 1489 | 0.110 |
Why?
|
| Electronics | 2 | 2023 | 58 | 0.110 |
Why?
|
| Alphapapillomavirus | 2 | 2012 | 171 | 0.110 |
Why?
|
| Urban Population | 1 | 2014 | 269 | 0.110 |
Why?
|
| Predictive Value of Tests | 3 | 2012 | 4892 | 0.110 |
Why?
|
| Regression Analysis | 3 | 2011 | 1546 | 0.110 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2013 | 90 | 0.110 |
Why?
|
| Blood Preservation | 1 | 2012 | 54 | 0.110 |
Why?
|
| Algorithms | 3 | 2021 | 3890 | 0.110 |
Why?
|
| Inflammation | 3 | 2013 | 2522 | 0.110 |
Why?
|
| Metabolic Detoxication, Phase I | 1 | 2012 | 10 | 0.110 |
Why?
|
| Metabolic Detoxication, Phase II | 1 | 2012 | 17 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 2594 | 0.110 |
Why?
|
| Tanzania | 2 | 2023 | 68 | 0.110 |
Why?
|
| Cyclooxygenase 2 | 2 | 2013 | 483 | 0.110 |
Why?
|
| Blood Specimen Collection | 1 | 2012 | 93 | 0.100 |
Why?
|
| Hormone Replacement Therapy | 1 | 2014 | 205 | 0.100 |
Why?
|
| Solvents | 1 | 2012 | 66 | 0.100 |
Why?
|
| Biomedical Technology | 1 | 2012 | 35 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 2045 | 0.100 |
Why?
|
| Likelihood Functions | 1 | 2012 | 233 | 0.100 |
Why?
|
| Janus Kinase 2 | 1 | 2016 | 679 | 0.100 |
Why?
|
| Immunoglobulin M | 1 | 2013 | 347 | 0.100 |
Why?
|
| DNA | 1 | 2020 | 2693 | 0.100 |
Why?
|
| 5-Lipoxygenase-Activating Proteins | 1 | 2011 | 4 | 0.100 |
Why?
|
| Psychometrics | 1 | 2016 | 937 | 0.100 |
Why?
|
| Poliovirus Vaccines | 1 | 2011 | 16 | 0.100 |
Why?
|
| Coinfection | 1 | 2013 | 189 | 0.100 |
Why?
|
| Haemophilus Vaccines | 1 | 2011 | 40 | 0.100 |
Why?
|
| Prostaglandin-E Synthases | 1 | 2011 | 28 | 0.100 |
Why?
|
| Breast Feeding | 2 | 2023 | 239 | 0.100 |
Why?
|
| Proton Therapy | 1 | 2021 | 1577 | 0.100 |
Why?
|
| Professional Competence | 1 | 2012 | 136 | 0.100 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2016 | 406 | 0.100 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 102 | 0.100 |
Why?
|
| Hepatitis B Vaccines | 1 | 2011 | 51 | 0.100 |
Why?
|
| Birth Order | 1 | 2010 | 8 | 0.090 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 1910 | 0.090 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2010 | 23 | 0.090 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2011 | 81 | 0.090 |
Why?
|
| Linear Models | 1 | 2013 | 1085 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2016 | 1823 | 0.090 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 460 | 0.090 |
Why?
|
| HMGA2 Protein | 1 | 2010 | 19 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 1294 | 0.090 |
Why?
|
| Oligodendroglioma | 1 | 2010 | 106 | 0.090 |
Why?
|
| Cytokines | 1 | 2019 | 2809 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2016 | 5437 | 0.090 |
Why?
|
| Age of Onset | 1 | 2012 | 827 | 0.090 |
Why?
|
| Disease Progression | 3 | 2021 | 6682 | 0.090 |
Why?
|
| Body Height | 2 | 2017 | 231 | 0.090 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 4320 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2017 | 1154 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 244 | 0.090 |
Why?
|
| In Situ Hybridization | 2 | 2012 | 1037 | 0.090 |
Why?
|
| Genetic Heterogeneity | 1 | 2011 | 318 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 1870 | 0.090 |
Why?
|
| Proteins | 1 | 2018 | 1963 | 0.090 |
Why?
|
| Censuses | 2 | 2022 | 19 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 3022 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 2864 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2013 | 558 | 0.090 |
Why?
|
| Siblings | 1 | 2010 | 285 | 0.080 |
Why?
|
| Health Behavior | 1 | 2013 | 603 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2022 | 5542 | 0.080 |
Why?
|
| Time Factors | 4 | 2016 | 12926 | 0.080 |
Why?
|
| Platelet Count | 2 | 2022 | 490 | 0.080 |
Why?
|
| Mexico | 2 | 2021 | 259 | 0.080 |
Why?
|
| Phenotype | 4 | 2023 | 6295 | 0.080 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2010 | 316 | 0.080 |
Why?
|
| Image Cytometry | 1 | 2007 | 47 | 0.080 |
Why?
|
| Cambodia | 2 | 2018 | 12 | 0.080 |
Why?
|
| Neoplasm Staging | 5 | 2021 | 13658 | 0.080 |
Why?
|
| Dacarbazine | 1 | 2009 | 485 | 0.080 |
Why?
|
| DNA Helicases | 1 | 2010 | 434 | 0.080 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2016 | 1105 | 0.070 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 5687 | 0.070 |
Why?
|
| Transcription Factors | 2 | 2019 | 5270 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2023 | 1819 | 0.070 |
Why?
|
| Body Weight | 2 | 2017 | 1293 | 0.070 |
Why?
|
| Optics and Photonics | 1 | 2007 | 146 | 0.070 |
Why?
|
| ROC Curve | 3 | 2019 | 1183 | 0.070 |
Why?
|
| CpG Islands | 2 | 2020 | 633 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2022 | 6550 | 0.070 |
Why?
|
| Transplantation, Homologous | 1 | 2012 | 2843 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 588 | 0.070 |
Why?
|
| Nervous System | 1 | 2007 | 165 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 10035 | 0.070 |
Why?
|
| Vaccines | 1 | 2011 | 389 | 0.070 |
Why?
|
| Infusions, Intravenous | 2 | 2021 | 1382 | 0.070 |
Why?
|
| International Agencies | 2 | 2018 | 107 | 0.070 |
Why?
|
| Hemochromatosis Protein | 2 | 2015 | 23 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 3981 | 0.070 |
Why?
|
| Neutropenia | 1 | 2009 | 968 | 0.060 |
Why?
|
| Radiotherapy | 1 | 2012 | 1824 | 0.060 |
Why?
|
| Computational Biology | 2 | 2021 | 1271 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2007 | 1053 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2023 | 32848 | 0.060 |
Why?
|
| Medical History Taking | 2 | 2019 | 173 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2012 | 862 | 0.060 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 11538 | 0.060 |
Why?
|
| Disease-Free Survival | 4 | 2019 | 10001 | 0.060 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 1399 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2007 | 1643 | 0.060 |
Why?
|
| Uganda | 1 | 2023 | 74 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2005 | 354 | 0.060 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2023 | 78 | 0.060 |
Why?
|
| Mediator Complex | 1 | 2023 | 69 | 0.060 |
Why?
|
| Nevirapine | 1 | 2022 | 17 | 0.060 |
Why?
|
| Loss of Function Mutation | 1 | 2023 | 132 | 0.060 |
Why?
|
| Viral Vaccines | 1 | 2005 | 304 | 0.050 |
Why?
|
| Transcriptome | 2 | 2021 | 1859 | 0.050 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2023 | 61 | 0.050 |
Why?
|
| HIV-1 | 2 | 2018 | 653 | 0.050 |
Why?
|
| Philadelphia | 1 | 2022 | 38 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2022 | 55 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 4654 | 0.050 |
Why?
|
| Survivorship | 1 | 2022 | 109 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2023 | 3033 | 0.050 |
Why?
|
| Extremities | 1 | 2023 | 303 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2023 | 216 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 2403 | 0.050 |
Why?
|
| Melanoma | 1 | 2019 | 5317 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2010 | 2022 | 0.050 |
Why?
|
| Penicillins | 1 | 2022 | 143 | 0.050 |
Why?
|
| Computers | 1 | 2021 | 141 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 129 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 7548 | 0.050 |
Why?
|
| Phosphotransferases | 1 | 2021 | 84 | 0.050 |
Why?
|
| Growth Hormone | 1 | 2021 | 226 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 3639 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 3976 | 0.050 |
Why?
|
| Executive Function | 1 | 2021 | 160 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 1323 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 462 | 0.050 |
Why?
|
| Virus Replication | 1 | 2023 | 709 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 1217 | 0.050 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 190 | 0.040 |
Why?
|
| DNA Ligase ATP | 2 | 2010 | 51 | 0.040 |
Why?
|
| Ikaros Transcription Factor | 1 | 2019 | 54 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 74 | 0.040 |
Why?
|
| Arkansas | 1 | 2019 | 58 | 0.040 |
Why?
|
| Biopsy | 1 | 2007 | 3443 | 0.040 |
Why?
|
| Forecasting | 1 | 2022 | 694 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2012 | 3869 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 146 | 0.040 |
Why?
|
| Angola | 1 | 2018 | 5 | 0.040 |
Why?
|
| Adiposity | 1 | 2020 | 237 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 90 | 0.040 |
Why?
|
| Heterozygote | 1 | 2022 | 1020 | 0.040 |
Why?
|
| Endemic Diseases | 1 | 2018 | 67 | 0.040 |
Why?
|
| Sleep | 1 | 2021 | 413 | 0.040 |
Why?
|
| Fetal Development | 1 | 2020 | 120 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 773 | 0.040 |
Why?
|
| Botswana | 1 | 2018 | 87 | 0.040 |
Why?
|
| Protons | 1 | 2021 | 473 | 0.040 |
Why?
|
| Telomerase | 1 | 2021 | 525 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 3578 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5319 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 166 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2023 | 1152 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 8873 | 0.040 |
Why?
|
| Waist-Height Ratio | 1 | 2017 | 4 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 854 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1274 | 0.040 |
Why?
|
| Guatemala | 1 | 2017 | 67 | 0.040 |
Why?
|
| Washington | 1 | 2017 | 70 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 684 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 651 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2017 | 46 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 476 | 0.040 |
Why?
|
| Mutation | 3 | 2022 | 15179 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 712 | 0.040 |
Why?
|
| Hematology | 1 | 2018 | 104 | 0.040 |
Why?
|
| Collodion | 1 | 2016 | 16 | 0.040 |
Why?
|
| Paper | 1 | 2016 | 11 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2018 | 875 | 0.040 |
Why?
|
| Virus Activation | 1 | 2018 | 228 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2018 | 203 | 0.040 |
Why?
|
| Cross Infection | 1 | 2021 | 544 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8865 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 470 | 0.040 |
Why?
|
| Spain | 1 | 2016 | 113 | 0.040 |
Why?
|
| Costa Rica | 1 | 2016 | 13 | 0.040 |
Why?
|
| Greece | 1 | 2016 | 22 | 0.040 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2016 | 18 | 0.040 |
Why?
|
| Amino Acids | 1 | 2019 | 728 | 0.040 |
Why?
|
| Egypt | 1 | 2016 | 42 | 0.040 |
Why?
|
| New Zealand | 1 | 2016 | 60 | 0.030 |
Why?
|
| Proteome | 1 | 2020 | 561 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2016 | 101 | 0.030 |
Why?
|
| France | 1 | 2016 | 108 | 0.030 |
Why?
|
| Germany | 1 | 2016 | 111 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 3001 | 0.030 |
Why?
|
| Condoms | 1 | 2016 | 53 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2022 | 787 | 0.030 |
Why?
|
| Inhalation Exposure | 1 | 2015 | 41 | 0.030 |
Why?
|
| Carcinoma, Large Cell | 1 | 2016 | 94 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 236 | 0.030 |
Why?
|
| Geographic Information Systems | 1 | 2015 | 57 | 0.030 |
Why?
|
| Thailand | 1 | 2015 | 32 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2024 | 1589 | 0.030 |
Why?
|
| Housing | 1 | 2015 | 61 | 0.030 |
Why?
|
| Austria | 1 | 2015 | 29 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 6942 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 1581 | 0.030 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2016 | 106 | 0.030 |
Why?
|
| Bleomycin | 1 | 2016 | 467 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 2146 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2018 | 557 | 0.030 |
Why?
|
| Neutrophils | 1 | 2019 | 835 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 1099 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2019 | 1234 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 3842 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 698 | 0.030 |
Why?
|
| Animals | 4 | 2020 | 59536 | 0.030 |
Why?
|
| Family | 1 | 2017 | 736 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2016 | 556 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 6009 | 0.030 |
Why?
|
| Legislation as Topic | 1 | 2012 | 6 | 0.030 |
Why?
|
| Mood Disorders | 1 | 2014 | 163 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 2352 | 0.030 |
Why?
|
| Motivation | 1 | 2016 | 499 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 49 | 0.030 |
Why?
|
| Vomiting | 1 | 2014 | 354 | 0.030 |
Why?
|
| Glutathione Peroxidase | 1 | 2012 | 61 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 627 | 0.030 |
Why?
|
| Microscopy, Interference | 1 | 2011 | 16 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 3719 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2014 | 481 | 0.030 |
Why?
|
| Consensus | 1 | 2016 | 978 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2016 | 966 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2013 | 269 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2014 | 546 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 4971 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 4938 | 0.020 |
Why?
|
| Monitoring, Immunologic | 1 | 2010 | 47 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2010 | 105 | 0.020 |
Why?
|
| Public Health | 1 | 2012 | 299 | 0.020 |
Why?
|
| Cell Separation | 1 | 2012 | 612 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 2738 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2009 | 69 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2016 | 3536 | 0.020 |
Why?
|
| Decision Trees | 1 | 2010 | 178 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 276 | 0.020 |
Why?
|
| Remission Induction | 1 | 2016 | 3569 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2010 | 102 | 0.020 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2009 | 60 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2009 | 62 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 3101 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2010 | 149 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 4053 | 0.020 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2009 | 66 | 0.020 |
Why?
|
| Educational Status | 1 | 2010 | 397 | 0.020 |
Why?
|
| Electromagnetic Fields | 1 | 2008 | 50 | 0.020 |
Why?
|
| Cell Phone | 1 | 2008 | 45 | 0.020 |
Why?
|
| Seasons | 1 | 2010 | 340 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2009 | 172 | 0.020 |
Why?
|
| Brain | 1 | 2021 | 4113 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 170 | 0.020 |
Why?
|
| Endonucleases | 1 | 2009 | 178 | 0.020 |
Why?
|
| Equipment Design | 1 | 2011 | 1204 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2013 | 808 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 1148 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2009 | 237 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 324 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 2195 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 673 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 4744 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2010 | 992 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 1016 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 14551 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2010 | 1085 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 4298 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 4143 | 0.010 |
Why?
|
| Mice | 2 | 2013 | 34495 | 0.010 |
Why?
|
| Apoptosis | 1 | 2015 | 7591 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 7222 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2013 | 3341 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 7789 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 11965 | 0.010 |
Why?
|